{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:19:49Z","timestamp":1761581989104,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Roche"},{"name":"MSD"},{"name":"AstraZeneca"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Thymic squamous cell carcinoma (TSQCC), accounting for 70\u201380% of thymic carcinoma cases, is distinct from thymoma. However, differential diagnosis for type B3 thymoma is sometimes challenging, even with established markers for TSQCC, including KIT and CD5, which are expressed in\u2009~\u200980% of TSQCCs and\u2009~\u20093% of thymomas. Novel TSQCC-specific markers would facilitate precise diagnosis and optimal treatment. Herein, we found that preferentially expressed antigen in melanoma (PRAME) may be a novel TSQCC-specific diagnostic marker. We comprehensively profiled 770 immune-related mRNAs in 10 patients with TSQCC and two healthy controls, showing that <jats:italic>PRAME<\/jats:italic> and <jats:italic>KIT<\/jats:italic> were significantly upregulated in TSQCC (adjusted <jats:italic>p<\/jats:italic> values\u2009=\u20090.045 and 0.0011, respectively). We then examined PRAME expression in 17 TSQCCs and 116 thymomas via immunohistochemistry. All 17 (100%) TSQCCs displayed diffuse and strong PRAME expression, whereas eight of 116 (6.8%) thymomas displayed focal and weak expression (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). KIT and CD5 were positive in 17 (100%) and 16 (94.1%) TSQCCs, respectively, whereas one (0.9%) type B3 thymoma showed double positivity for KIT and CD5. The KIT-\/CD5-positive type B3 thymoma was negative for PRAME. Thus, combinatorial evaluation of PRAME with KIT and CD5 may facilitate a more precise diagnosis of TSQCC.<\/jats:p>","DOI":"10.1038\/s41598-020-69260-z","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T10:05:06Z","timestamp":1595498706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Preferentially expressed antigen in melanoma as a novel diagnostic marker differentiating thymic squamous cell carcinoma from thymoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Yohei","family":"Taniguchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuaki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohito","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Ryota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Utsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsumi","family":"Maru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruaki","family":"Hino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Tsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Murakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,23]]},"reference":[{"key":"69260_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejca.2007.11.004","volume":"44","author":"WK de Jong","year":"2008","unstructured":"de Jong, W. K. et al. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur. J. Cancer 44, 123\u2013130 (2008).","journal-title":"Eur. J. Cancer"},{"key":"69260_CR2","volume-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart 7","author":"WD Travis","year":"2015","unstructured":"Travis, W. D., Brambilla, E., Burke, A. P., Marx, A. & Nicholson, A. G. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart 7 4th edn. (IARC, Lyon, 2015).","edition":"4"},{"key":"69260_CR3","unstructured":"Cancer Registry and Statistics. Cancer Information Service, National Cancer Center, Japan. [Cited October 15, 2019]. https:\/\/ganjoho.jp\/reg_stat\/statistics\/brochure\/monitoring.html"},{"key":"69260_CR4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ejcts\/ezv239","volume":"49","author":"T Hishida","year":"2016","unstructured":"Hishida, T. et al. Japanese Association for Research on the Thymus (JART). Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide Database Study. Eur. J. Cardiothorac. Surg. 49, 835\u2013841 (2016).","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"69260_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3960\/jslrt.53.9","volume":"53","author":"A Hayashi","year":"2013","unstructured":"Hayashi, A. et al. The evaluation of immunohistochemical markers and thymic cortical microenvironmental cells in distinguishing thymic carcinoma from type b3 thymoma or lung squamous cell carcinoma. J. Clin. Exp. Hematopathol. 53, 9\u201319 (2013).","journal-title":"J. Clin. Exp. Hematopathol."},{"key":"69260_CR6","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/modpathol.2009.105","volume":"22","author":"M Kojika","year":"2009","unstructured":"Kojika, M. et al. Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms. Mod. Pathol. 22, 1341\u20131350 (2009).","journal-title":"Mod. Pathol."},{"key":"69260_CR7","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1378\/chest.128.1.140","volume":"128","author":"K Nakagawa","year":"2005","unstructured":"Nakagawa, K. et al. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest 128, 140\u2013144 (2005).","journal-title":"Chest"},{"key":"69260_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/path.1514","volume":"202","author":"CC Pan","year":"2004","unstructured":"Pan, C. C., Chen, P. C. & Chiang, H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J. Pathol. 202, 375\u2013381 (2004).","journal-title":"J. Pathol."},{"key":"69260_CR9","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.prp.2016.09.005","volume":"212","author":"MJ Du","year":"2016","unstructured":"Du, M. J., Shen, Q., Yin, H., Rao, Q. & Zhou, M. X. Diagnostic roles of MUC1 and GLUT1 in differentiating thymic carcinoma from type B3 thymoma. Pathol. Res. Pract. 212, 1048\u20131051 (2016).","journal-title":"Pathol. Res. Pract."},{"key":"69260_CR10","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/carcin\/bgx094","volume":"38","author":"M Saito","year":"2017","unstructured":"Saito, M. et al. The genomic and epigenomic landscape in thymic carcinoma. Carcinogenesis 38, 1084\u20131091 (2017).","journal-title":"Carcinogenesis"},{"key":"69260_CR11","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/ng.3016","volume":"46","author":"I Petrini","year":"2014","unstructured":"Petrini, I. et al. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat. Genet. 46, 844\u2013849 (2014).","journal-title":"Nat. Genet."},{"key":"69260_CR12","doi-asserted-by":"publisher","first-page":"7336","DOI":"10.1038\/srep07336","volume":"4","author":"Y Wang","year":"2014","unstructured":"Wang, Y. et al. Mutations of epigenetic regulatory genes are common in thymic carcinomas. Sci. Rep. 4, 7336 (2014).","journal-title":"Sci. Rep."},{"key":"69260_CR13","doi-asserted-by":"publisher","first-page":"S286","DOI":"10.1097\/JTO.0b013e3181f209a8","volume":"10","author":"P Str\u00f6bel","year":"2010","unstructured":"Str\u00f6bel, P., Hohenberger, P. & Marx, A. Thymoma and thymic carcinoma: molecular pathology and targeted therapy. J. Thorac. Oncol. 10, S286\u2013S290 (2010).","journal-title":"J. Thorac. Oncol."},{"key":"69260_CR14","doi-asserted-by":"publisher","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","volume":"15","author":"N Girard","year":"2009","unstructured":"Girard, N. et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin. Cancer Res. 15, 6790\u20136799 (2009).","journal-title":"Clin. Cancer Res."},{"key":"69260_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S1074-7613(00)80426-4","volume":"6","author":"H Ikeda","year":"1997","unstructured":"Ikeda, H. et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6, 199\u2013208 (1997).","journal-title":"Immunity"},{"key":"69260_CR16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","volume":"122","author":"MT Epping","year":"2005","unstructured":"Epping, M. T. et al. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 122, 835\u2013847 (2005).","journal-title":"Cell"},{"key":"69260_CR17","doi-asserted-by":"publisher","first-page":"296","DOI":"10.2174\/156652413804810727","volume":"13","author":"DD De Carvalho","year":"2013","unstructured":"De Carvalho, D. D., Mello, B. P., Pereira, W. O. & Amarante-Mendes, G. P. PRAME\/EZH2-mediated regulation of TRAIL: a new target for cancer therapy. Curr. Mol. Med. 13, 296\u2013304 (2013).","journal-title":"Curr. Mol. Med."},{"key":"69260_CR18","first-page":"4090","volume":"58","author":"E Neumann","year":"1998","unstructured":"Neumann, E. et al. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?. Cancer Res. 58, 4090\u20134095 (1998).","journal-title":"Cancer Res."},{"key":"69260_CR19","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","volume":"42","author":"C Lezcano","year":"2018","unstructured":"Lezcano, C., Jungbluth, A. A., Nehal, K. S., Hollmann, T. J. & Busam, K. J. PRAME expression in melanocytic tumors. Am. J. Surg. Pathol. 42, 1456\u20131465 (2018).","journal-title":"Am. J. Surg. Pathol."},{"key":"69260_CR20","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1158\/1078-0432.CCR-03-0813","volume":"10","author":"A Oberthuer","year":"2004","unstructured":"Oberthuer, A., Hero, B., Spitz, R., Berthold, F. & Fischer, M. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin. Cancer Res. 10, 4307\u20134313 (2004).","journal-title":"Clin. Cancer Res."},{"key":"69260_CR21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/cjp2.16","volume":"1","author":"K Iura","year":"2015","unstructured":"Iura, K. et al. Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma. J. Pathol. Clin. Res. 1, 144\u2013159 (2015).","journal-title":"J. Pathol. Clin. Res."},{"key":"69260_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.humpath.2016.12.006","volume":"61","author":"K Iura","year":"2017","unstructured":"Iura, K. et al. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1. Hum. Pathol. 61, 130\u2013139 (2017).","journal-title":"Hum. Pathol."},{"key":"69260_CR23","first-page":"665","volume":"39","author":"E Sakurai","year":"2011","unstructured":"Sakurai, E. et al. Downregulation of microRNA-211 is involved in expression of preferentially expressed antigen of melanoma in melanoma cells. Int. J. Oncol. 39, 665\u2013672 (2011).","journal-title":"Int. J. Oncol."},{"key":"69260_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/ajh.21915","volume":"86","author":"JM Gerber","year":"2011","unstructured":"Gerber, J. M. et al. Characterization of chronic myeloid leukemia stem cells. Am. J. Hematol. 86, 31\u201337 (2011).","journal-title":"Am. J. Hematol."},{"key":"69260_CR25","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.3892\/ol.2017.5790","volume":"13","author":"YZ Qin","year":"2017","unstructured":"Qin, Y. Z., Zhang, Y. H., Qin, X. Y. & Zhu, H. H. Methylation pattern of preferentially expressed antigen of melanoma in acute myeloid leukemia and myelodysplastic syndromes. Oncol. Lett. 13, 2823\u20132830 (2017).","journal-title":"Oncol. Lett."},{"key":"69260_CR26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S0014-5793(00)01112-1","volume":"466","author":"K Watari","year":"2000","unstructured":"Watari, K. et al. Identification of a melanoma antigen, PRAME, as a BCR\/ABL-inducible gene. FEBS Lett. 466, 367\u2013371 (2000).","journal-title":"FEBS Lett."},{"key":"69260_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/onc.2010.409","volume":"30","author":"DD De Carvalho","year":"2011","unstructured":"De Carvalho, D. D. et al. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. Oncogene 30, 223\u2013233 (2011).","journal-title":"Oncogene"},{"key":"69260_CR28","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1038\/bcj.2011.12","volume":"1","author":"B Brackertz","year":"2011","unstructured":"Brackertz, B. et al. FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes. Blood Cancer J. 1, e11 (2011).","journal-title":"Blood Cancer J."},{"key":"69260_CR29","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1016\/j.jtho.2016.08.120","volume":"11","author":"JL Pujol","year":"2016","unstructured":"Pujol, J. L. et al. Safety and immunogenicity of the PRAME cancer immunotherapeutic in patients with resected non-small cell lung cancer: a phase I dose escalation study. J. Thorac. Oncol. 11, 2208\u20132217 (2016).","journal-title":"J. Thorac. Oncol."},{"key":"69260_CR30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1001\/jamaophthalmol.2017.0729","volume":"135","author":"G Gezgin","year":"2017","unstructured":"Gezgin, G. et al. PRAME as a potential target for immunotherapy in metastatic uveal melanoma. JAMA Ophthalmol. 135, 541\u2013549 (2017).","journal-title":"JAMA Ophthalmol."},{"key":"69260_CR31","doi-asserted-by":"publisher","first-page":"e000068","DOI":"10.1136\/esmoopen-2016-000068","volume":"1","author":"R Gutzmer","year":"2016","unstructured":"Gutzmer, R. et al. Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. ESMO Open 1, e000068 (2016).","journal-title":"ESMO Open"},{"key":"69260_CR32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/bjc.2012.215","volume":"107","author":"L Dyrskj\u00f8t","year":"2012","unstructured":"Dyrskj\u00f8t, L. et al. Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma. Br. J. Cancer 107, 116\u2013122 (2012).","journal-title":"Br. J. Cancer"},{"key":"69260_CR33","doi-asserted-by":"publisher","first-page":"e55897","DOI":"10.1371\/journal.pone.0055897","volume":"8","author":"S Kewitz","year":"2013","unstructured":"Kewitz, S. & Staege, M. S. Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells. PLoS ONE 8, e55897 (2013).","journal-title":"PLoS ONE"},{"key":"69260_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s12185-014-1593-z","volume":"100","author":"K Mitsuhashi","year":"2014","unstructured":"Mitsuhashi, K., Masuda, A., Wang, Y. H., Shiseki, M. & Motoji, T. Prognostic significance of PRAME expression based on immunohistochemistry for diffuse large B-cell lymphoma patients treated with R-CHOP therapy. Int. J. Hematol. 100, 88\u201395 (2014).","journal-title":"Int. J. Hematol."},{"key":"69260_CR35","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","volume":"16","author":"A Thomas","year":"2015","unstructured":"Thomas, A. et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol. 16, 177\u2013186 (2015).","journal-title":"Lancet Oncol."},{"key":"69260_CR36","first-page":"88","volume":"100","author":"JT Salter","year":"2014","unstructured":"Salter, J. T. et al. Imatinib for the treatment of thymic carcinoma. J. Clin. Oncol. 100, 88\u201395 (2014).","journal-title":"J. Clin. Oncol."},{"key":"69260_CR37","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1056\/NEJM200408053510621","volume":"351","author":"AM Clark","year":"2004","unstructured":"Clark, A. M., Jamieson, R. & Findlay, I. N. Registries and informed consent. N. Engl. J. Med. 351, 612\u2013614 (2004).","journal-title":"N. Engl. J. Med."},{"key":"69260_CR38","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/his.13802","volume":"74","author":"H Ryota","year":"2019","unstructured":"Ryota, H. et al. Clinicopathological and immunological features of follicular pancreatitis-a distinct disease entity characterized by Th17 activation. Histopathology 74, 709\u2013717 (2019).","journal-title":"Histopathology"},{"key":"69260_CR39","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1214\/aos\/1013699998","volume":"29","author":"Y Benjamini","year":"2001","unstructured":"Benjamini, Y. & Yekutieli, D. The control of the false discovery rate in multiple testing under dependency. Ann. Stat. 29, 1165\u20131188 (2001).","journal-title":"Ann. Stat."},{"key":"69260_CR40","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.pan.2019.03.001","volume":"19","author":"Y Hasimoto","year":"2019","unstructured":"Hasimoto, Y. et al. Adiophilin expression is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma: an immunohistochemical analysis. Pancreatology 19, 443\u2013448 (2019).","journal-title":"Pancreatology"},{"key":"69260_CR41","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 48, 452\u2013458 (2013).","journal-title":"Bone Marrow Transplant."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69260-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69260-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69260-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T14:15:37Z","timestamp":1670336137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-69260-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,23]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["69260"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-69260-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2020,7,23]]},"assertion":[{"value":"23 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Tsuta has received research funding from Ono Pharmaceutical Co., Ltd., as well as personal fees from Roche, MSD, and AstraZeneca. The remaining authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12286"}}